Archives: 2025-12-12

WHO expert group’s new analysis reaffirms there is no link between vaccines and autism

New analysis from a WHO global expert committee on vaccine safety has found that, based on available evidence, no causal link exists between vaccines and autism spectrum disorders (ASD). The conclusion reaffirms WHO’s position that childhood vaccines do not cause autism. The Global Advisory Committee on Vaccine Safety (GACVS), established in 1999, brings together international

Read More


Oregon Health Science University study: CAR-T therapy shows long-term survival for patients with lymphoma

Five-year data from clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions in high-risk patients A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult patients with relapsed or refractory large B-cell lymphoma, even

Read More


University of British Columbia researchers uncover how statins harm muscles—and how to stop it 

Study reveals how cholesterol-lowering drugs can trigger muscle damage—and point to a way to make them safer.  Statins have transformed heart health, saving millions of lives by lowering cholesterol and reducing the risk of heart attacks and strokes. But for many patients, these drugs come with a troubling downside: muscle pain, weakness and, in rare

Read More


FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

The U.S. Food and Drug Administration announced it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). Omisirge is indicated for adults and pediatric patients 12 years and older with hematologic malignancies and now is approved for adults and pediatric patients six years and

Read More


FDA and EMA Approve First Gene Therapy Treatment for Wiskott-Aldrich Syndrome to Fondazione Telethon ETS

Agency exercises regulatory flexibility to address unmet need for rare, life-threatening disease The U.S. Food and Drug Administration approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for pediatric patients six months and older and adults with WAS who have a mutation in the WAS gene and

Read More